Merck and BioNTech extend partnership to accelerated supply of lipids for Pfizer-BioNTech COVID-19 vaccine

Merck and BioNTech are further expanding their strategic partnership to accelerate the supply of urgently needed lipids for the production of the Pfizer-BioNTech Covid-19 Vaccine (BNT162b2).

Merck, in close collaboration with BioNTech, will significantly accelerate the supply of urgently needed lipids and increase the amount of lipid delivery towards the end of 2021.

Lipids are critical to the drug delivery system of mRNA therapies to the body for a vaccine to be effective. Only very few companies in the world are currently able to produce custom lipids in significant quantities and according to the highest quality requirements needed for vaccine production.

“What unites BioNTech and Merck is our strong belief in mRNA technology and our trustful collaboration in vaccine development,” said Stefan Oschmann, Chairman of the Executive Board and CEO of Merck.

“We are convinced that now is the time to pull together to supply as much vaccine as possible to the world. Extraordinary times like these require bold steps, and we are ready to take these steps to tackle one of the biggest challenges of humanity.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Related news